MedtronicMDT
MDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 203 | Existing positions closed: 143
1.04% more ownership
Funds ownership: 81.43% [Q3] → 82.47% (+1.04%) [Q4]
7% less call options, than puts
Call options by funds: $586M | Put options by funds: $632M
2% less funds holding
Funds holding: 2,034 [Q3] → 1,997 (-37) [Q4]
6% less funds holding in top 10
Funds holding in top 10: 31 [Q3] → 29 (-2) [Q4]
12% less capital invested
Capital invested by funds: $96B [Q3] → $84.6B (-$11.4B) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 741 | Existing positions reduced: 856
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$89
1%
downside
Avg. target
$98
9%
upside
High target
$109
21%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target | 17%upside $105 | Outperform Reiterated | 19 Feb 2025 |
UBS Danielle Antalffy 69% 1-year accuracy 9 / 13 met price target | 6%upside $95 | Neutral Maintained | 19 Feb 2025 |
Baird David Rescott 89% 1-year accuracy 16 / 18 met price target | 1%upside $91 | Neutral Maintained | 19 Feb 2025 |
Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target | 1%downside $89 | Hold Maintained | 18 Dec 2024 |
Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target | 21%upside $109 | Overweight Maintained | 26 Nov 2024 |
Financial journalist opinion
Based on 33 articles about MDT published over the past 30 days
Neutral
The Motley Fool
20 hours ago
Is Medtronic Stock a Buy?
Medical device manufacturer Medtronic (MDT 2.59%) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a diverse portfolio of products that includes hospital equipment and devices for cardiovascular care and diabetes.
Positive
MarketBeat
23 hours ago
Medtronic's Expansion Gains Momentum—Time for a Market Shift?
Medtronic's NYSE: MDT growth efforts and investments in medical technology innovation are starting to pay off. The company's pulsed field ablation (PFA) technology is a key growth driver, strengthening both its cardiac segment and overall business expansion.
Positive
The Motley Fool
2 days ago
The Smartest Dividend Stocks to Buy With $1,000 Right Now
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers?
Negative
The Motley Fool
3 days ago
Why Medtronic Stock Is Sinking Today
Shares of Medtronic (MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday.
Positive
Zacks Investment Research
3 days ago
Empire State Manufacturing Increase More Than Expected
Pre-market futures are starting a new holiday-shortened trading week higher, with all four major indexes currently riding in the green. The Dow is +81 points at this hour, the S&P 500 is +23, the Nasdaq +96 points and the small-cap Russell 2000 +9.
Neutral
Seeking Alpha
3 days ago
Medtronic plc (MDT) Q3 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q3 2025 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head of Investor Relations Geoff Martha - Chairman and Chief Executive Officer Gary Corona - Interim Chief Financial Officer Brad Welnick - Vice President, Investor Relations Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Mike Marinaro - Executive Vice President and President, Medical Surgical Portfolio and Americas Conference Call Participants Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Vijay Kumar - Evercore ISI Travis Steed - Bank of America Matt Miksic - Barclays Josh Jennings - TD Cowen David Rescott - Baird Shagun Singh - RBC Capital Markets Pito Chickering - Deutsche Bank Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us for our Fiscal ‘25 Third Quarter Video Earnings Webcast.
Positive
Zacks Investment Research
3 days ago
Here's What Key Metrics Tell Us About Medtronic (MDT) Q3 Earnings
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended January 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neutral
Zacks Investment Research
3 days ago
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.
Neutral
Benzinga
3 days ago
Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
Tuesday, Medtronic Plc MDT reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion.
Negative
Investors Business Daily
3 days ago
Why Medtronic Just Undercut Its Buy Zone With A 5% Drop
Medtronic stock skidded Tuesday after the medtech giant missed sales expectations, though profit came in well ahead of forecasts. The post Why Medtronic Just Undercut Its Buy Zone With A 5% Drop appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™